

Expr ss Mail Label No.: 4877US  
Date of Deposit: February 19, 2002

Modified Form 1449/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Serial Number	10/055,524
Filing Date	October 26, 2001
First Named Inventor	De Groot
Group Art Unit	
Examiner Name	Not Yet Assigned
Attorney Docket Number	17999-001DIV (BURF-17999)

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1*	5,886,320	03/23/99	Gallo, et al.			09/03/96
	A2*	5,876,731	03/2/99	Sia, et al.			06/05/95
	A3*	5,817,318	10/06/98	Sia, et al.			06/06/95

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

OTHER NON-PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	B1*	Germain & Margulies (1993). "The biochemistry and cell biology of antigen processing and presentation" <i>Ann. Rev. Immunol.</i> 11: 403-450.
	B2*	Falk, et al. (1991). "Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules" <i>Nature</i> 351: 290-296.
	B3*	Wilson, et al. (1998). "Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection" <i>AIDS Res. Hum. Retroviruses</i> 14: 925-937.
	B4*	McAdam, et al. (1998). "Cross-clade recognition of p55 by cytotoxic T lymphocytes in HIV-1 infection" <i>AIDS</i> 12: 571-579.
	B5*	Lynch, et al. (1998). "Cross-clade cytotoxic T cell response to Human Immunodeficiency Virus type 1 proteins among HLA disparate North Americans and Thais" <i>J Infect Dis.</i> 178: 1040-1046.
	B6*	Boyer, et al. (1998). "HIV-1 DNA based vaccine induces a CD8 mediated cross-clade CTRL response" <i>Dev. Biol. Stand.</i> 95: 147-153.
	B7*	Cao, et al. (1997). "Cytotoxic T-lymphocyte cross-reactivity among different Human Immunodeficiency Virus type 1 clades: Implications for vaccine development" <i>J. Virol.</i> 71: 8615-8623.
	B8*	Durali, et al. (1998). "Cross-reactions between the cytotoxic T-lymphocyte responses of Human Immunodeficiency Virus-infected African and European patients" <i>Virology</i> 72: 3547-3553.
	B9*	Koup (1994). "Virus escape from CTL recognition" <i>J. Exp. Med.</i> 180: 779-782.
	B10*	Dai, et al. (1992). "Mutation of Human Immunodeficiency Virus type 1 at amino acid 585 on gp41 results in loss of killing by CD8+ A24-restricted cytotoxic T lymphocytes" <i>J. Virol.</i> 66: 3151-3154.
	B11*	Johnson, et al. (1992). "Identification of overlapping HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the Human Immunodeficiency Virus type 1 envelope glycoprotein: Definition of minimum epitopes and analysis of the effects of sequence variation" <i>J. Exp. Med.</i> 175: 961-971.
	B12*	Jesdale, et al. (1997). "Matrix-based prediction of MHC-binding peptides: The EpiMatrix algorithm, reagent for HIV research" in <i>Vaccines</i> . (Cold Spring Harbor Press, Cold Spring Harbor, 1997).
	B13*	Schafer, et al. (1998). "Prediction of well-conserved HIV-1 ligands using matrix-based algorithm, EpiMatrix" <i>Vaccine</i> 16: 1-5.

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/351,036, filed July 9, 1999, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	Date Considered
	05/09/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

APR 04 2002

TECH CENTER 1600/290

